Developing sulfonium lipid nanoparticles as a novel platform for mrna delivery
Active Project Grant Awarded Last action
- Award ID
- R35GM160083
- Recipient
-
The Research Foundation For The State University Of New York UEI HYN3WD58HNN7 Part of The Research Foundation For The State University Of New York
- Awarding agency
-
National Institute of General Medical Sciences
National Institutes of Health, Department of Health and Human Services
- Obligated
- $896,500
Award facts
- Assistance listing
- 93.859 Biomedical Research and Research Training
- Completion date 25% complete
- Place of performance
- Syracuse, NY 13210, USA
Award details come from USAspending.gov.
Description
- Abstract
- Lipid nanoparticles (lnps) are the most clinically advanced system for mrna delivery, as highlighted by the FDA approvals of spikevax® and comirnaty®. However, there is no one-fit-all lipid design; lipids that perform well for one application may not work effectively across different cell types or medical conditions. This underscores the need to expand the lipid molecular toolbox to address evolving therapeutic challenges. By introducing sulfonium as a charge-carrying unit to replace traditional amines, we first demonstrated the safety and feasibility of using unconventional, non-amine-based sulfonium lipids for mrna delivery. Building on these promising results, we propose to further develop sulfonium lipid nanoparticles (slnps) as a new platform for mrna delivery. We will expand the chemical diversity of sulfonium lipids by incorporating novel building blocks, laying the groundwork for structure-activity relationship studies. Similar to amine-based lipids, variations in the head, linker, and tail structures of sulfonium lipids will likely affect self-assembly, cargo delivery, and biocompatibility. A detailed mechanistic investigation will uncover the unique physicochemical and biological properties of slnps. Additionally, we will explore the therapeutic potential of organ-targeting mrna/slnp formulations for treating acute lung injury (ALI) and acute respiratory distress syndrome (ards) in clinically relevant small animal models, providing robust preclinical evidence to pave the way for future translational research of slnp technology.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $448,250 | |
| Original award | $448,250 |
Quick answers
Who received award R35GM160083?
R35GM160083 was awarded to The Research Foundation For The State University Of New York by National Institute of General Medical Sciences (National Institutes of Health) on August 15, 2025.
How much is award R35GM160083 worth?
$896,500 has been obligated on R35GM160083.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award